The instruction for medical use
of LORAKTIV medicine
the Trade name
of Loraktiv
the International unlicensed
name Loratadin Lekarstvennaya a form
of the Tablet, 10 mg
Structure
One tablet contains
active agent - loratadin 10 mg,
excipients: calcium hydrophosphate, starch sodium glycollate, starch corn, starch corn (in the form of paste), the talc purified magnesium stearate.
Description
of the Tablet of an oval form, biconvex, white color.
Pharmacotherapeutic group
Antihistaminic drugs of systemic action others.
The code of automatic telephone exchange R06AX13
the Pharmacological
Pharmacokinetics Loratadin properties is quickly soaked up from digestive tract after intake, reaching peak concentration in plasma approximately in 1 hour. At reception with food the bioavailability of drug increases, time of achievement of peak concentration in plasma increases. Loratadin is exposed to extensive metabolism. The main metabolite, dezkarboetoksiloratadin, possesses expressed H1-gistaminoblokiruyushchim action. Elimination half-life of Loratadin and a dezkarboetoksiloratadin makes 12 hours and 18 hours, respectively. Loratadin contacts proteins of plasma, approximately for 98%, dezkarboetoksiloratadin to a lesser extent. Loratadin and his metabolites are defined in breast milk, but do not get through GEB, there are also no data which are authentically confirming its penetration through a placenta. Loratadin and his metabolites are removed with urine and a stake.
The pharmacodynamics
of Loraktiv - a blocker histamine H1 receptors is tricyclic antihistaminic drug of long action with selective antagonistic influence on peripheral histamine H1 receptors. Has antiallergic, antipruritic, anti-exudative effect. Reduces permeability of capillaries, prevents edematization of fabrics.
Indications
- seasonal and year-round allergic rhinitis and its symptoms (sneezing, an itching of a mucous membrane of a nose, cold, burning and an itching of eyes)
- conjunctivitis
- acute and chronic urticaria
- an allergic pruritic dermatosis: contact allergic dermatitis, chronic eczema
the Route of administration and doses
to Adults and children is more senior than 6 years: 10 mg (1 tablet) a day.
Duration of treatment is defined individually depending on duration of clinical manifestations.
Side effects
- dryness in a mouth, nausea, vomiting, gastritis
- increased fatigue, a headache, excitability (at children)
- allergic reactions
- drowsiness
- tachycardia
- it is rare: allopecia, abnormal liver functions, spasms, anaphylactic reactions.
Contraindications
- hypersensitivity to drug components
- pregnancy, the lactation period
- children's age up to 6 years.
Medicinal interactions
of Pharmakodinamicheskoye: at a concomitant use with Loraktiv alcohol does not exponentiate effect of alcohol on central nervous system.
Pharmacokinetic: at joint appointment Loraktiva with therapeutic doses of erythromycin, Cimetidinum and ketokonazol the increase in concentration of a loratadin in blood plasma without any collateral manifestations was observed.
Special instructions
to Patients with a liver or renal failure (glomerular filtration rate less than 30 ml/min.) appoint low doses (10 mg) every other day in connection with decrease in clearance of drug.
Influence of drug on ability to control of motor transport or work with mechanisms.
Considering emergence of side effects it is necessary to be careful at administration of drug at control of motor transport or work with other mechanisms.
Overdose
Symptoms: drowsiness, tachycardia, headache.
Treatment: the supporting and symptomatic treatment. To cause vomiting, then to appoint activated carbon, gastric lavage normal saline solution. Loratadin is not brought at a hemodialysis.
Form of release and packing
Primary packing: 10 tablets in blister strip packaging.
Secondary packing: 1 blister strip packaging with the instruction for medical use in cardboard packing.
To Store storage conditions in the dry, protected from light place at a temperature not over 250C.
To store out of children's reach!
3 years
not to apply a period of storage after an expiration date.
Prescription status
According to the prescription
of Proizvoditel Pletkhiko Pharmasyyutikalz Ltd / Plethico Pharmaceuticals Ltd
the location Address:
Dharavara, Kalariya 453,001, Indore (L. S.), India
Legal address:
37/37A, Indastrial Isteyt, Polograund, Indore (L. S.), 452,015, India
the Address of the organization accepting in the territory of the Republic of Kazakhstan consumers on quality of products:
Representation in RK TOO Rezlov LTD, Karaganda, Ermekov St. 116 A, office 10.
Ph. +7 (212) 442220, fax + 7 (212) 442221.
E-mail address of rezlov_ltd@mail.ru
of LORAKTIV medicine
the Trade name
of Loraktiv
the International unlicensed
name Loratadin Lekarstvennaya a form
of the Tablet, 10 mg
Structure
One tablet contains
active agent - loratadin 10 mg,
excipients: calcium hydrophosphate, starch sodium glycollate, starch corn, starch corn (in the form of paste), the talc purified magnesium stearate.
Description
of the Tablet of an oval form, biconvex, white color.
Pharmacotherapeutic group
Antihistaminic drugs of systemic action others.
The code of automatic telephone exchange R06AX13
the Pharmacological
Pharmacokinetics Loratadin properties is quickly soaked up from digestive tract after intake, reaching peak concentration in plasma approximately in 1 hour. At reception with food the bioavailability of drug increases, time of achievement of peak concentration in plasma increases. Loratadin is exposed to extensive metabolism. The main metabolite, dezkarboetoksiloratadin, possesses expressed H1-gistaminoblokiruyushchim action. Elimination half-life of Loratadin and a dezkarboetoksiloratadin makes 12 hours and 18 hours, respectively. Loratadin contacts proteins of plasma, approximately for 98%, dezkarboetoksiloratadin to a lesser extent. Loratadin and his metabolites are defined in breast milk, but do not get through GEB, there are also no data which are authentically confirming its penetration through a placenta. Loratadin and his metabolites are removed with urine and a stake.
The pharmacodynamics
of Loraktiv - a blocker histamine H1 receptors is tricyclic antihistaminic drug of long action with selective antagonistic influence on peripheral histamine H1 receptors. Has antiallergic, antipruritic, anti-exudative effect. Reduces permeability of capillaries, prevents edematization of fabrics.
Indications
- seasonal and year-round allergic rhinitis and its symptoms (sneezing, an itching of a mucous membrane of a nose, cold, burning and an itching of eyes)
- conjunctivitis
- acute and chronic urticaria
- an allergic pruritic dermatosis: contact allergic dermatitis, chronic eczema
the Route of administration and doses
to Adults and children is more senior than 6 years: 10 mg (1 tablet) a day.
Duration of treatment is defined individually depending on duration of clinical manifestations.
Side effects
- dryness in a mouth, nausea, vomiting, gastritis
- increased fatigue, a headache, excitability (at children)
- allergic reactions
- drowsiness
- tachycardia
- it is rare: allopecia, abnormal liver functions, spasms, anaphylactic reactions.
Contraindications
- hypersensitivity to drug components
- pregnancy, the lactation period
- children's age up to 6 years.
Medicinal interactions
of Pharmakodinamicheskoye: at a concomitant use with Loraktiv alcohol does not exponentiate effect of alcohol on central nervous system.
Pharmacokinetic: at joint appointment Loraktiva with therapeutic doses of erythromycin, Cimetidinum and ketokonazol the increase in concentration of a loratadin in blood plasma without any collateral manifestations was observed.
Special instructions
to Patients with a liver or renal failure (glomerular filtration rate less than 30 ml/min.) appoint low doses (10 mg) every other day in connection with decrease in clearance of drug.
Influence of drug on ability to control of motor transport or work with mechanisms.
Considering emergence of side effects it is necessary to be careful at administration of drug at control of motor transport or work with other mechanisms.
Overdose
Symptoms: drowsiness, tachycardia, headache.
Treatment: the supporting and symptomatic treatment. To cause vomiting, then to appoint activated carbon, gastric lavage normal saline solution. Loratadin is not brought at a hemodialysis.
Form of release and packing
Primary packing: 10 tablets in blister strip packaging.
Secondary packing: 1 blister strip packaging with the instruction for medical use in cardboard packing.
To Store storage conditions in the dry, protected from light place at a temperature not over 250C.
To store out of children's reach!
3 years
not to apply a period of storage after an expiration date.
Prescription status
According to the prescription
of Proizvoditel Pletkhiko Pharmasyyutikalz Ltd / Plethico Pharmaceuticals Ltd
the location Address:
Dharavara, Kalariya 453,001, Indore (L. S.), India
Legal address:
37/37A, Indastrial Isteyt, Polograund, Indore (L. S.), 452,015, India
the Address of the organization accepting in the territory of the Republic of Kazakhstan consumers on quality of products:
Representation in RK TOO Rezlov LTD, Karaganda, Ermekov St. 116 A, office 10.
Ph. +7 (212) 442220, fax + 7 (212) 442221.
E-mail address of rezlov_ltd@mail.ru
Related Products
